Introduction {#s1}
============

Wolfram syndrome 1 (WS1, MIM\# 222300) is a rare inherited disease, characterized by diabetes insipidus), diabetes mellitus (DM), optic atrophy (OA), and deafness, and is therefore also known as DIDMOAD. It was first described in 1938 ([@B40]). Other findings include cataracts, pigmentary retinopathy, hydronephrosis, hydroureter, neurogenic bladder, ataxia, and psychiatric disorders. Patients may also present with cardiomyopathy, hypothyroidism, and hypogonadism. The estimated prevalence ranges from 1:68,000 to 1:770,000 ([@B13]; [@B3]; [@B27]; [@B26]). The age at death varies from 25 to 49 years (median age is 30 years) and is usually due to brain stem atrophy resulting in respiratory failure ([@B3]). There is currently no effective treatment. The clinical diagnostic criteria for WS1 are juvenile-onset DM and OA. It can be easily misdiagnosed as type 1 DM before other symptoms, such as OA, present. It is crucial to combine genetic diagnosis with clinical manifestations to obtain an early diagnosis and confirmation of WS1.

WS1 is an autosomal recessive condition, caused by mutations in the *WFS1* gene \[Online Mendelian Inheritance in Man (OMIM) 606201\]. The *WFS1* gene is mapped to human chromosome 4p16.1 ([@B34]) and is composed of eight exons, spanning 33.4 kb of genomic DNA. Exon 8 is the largest exon, and exons 2--7 are small coding exons, and exon 1 is noncoding ([@B19]). *WFS1* encodes wolframin, a transmembrane protein that localizes primarily in endoplasmic reticulum (ER) membranes and is ubiquitously expressed at the highest levels in the brain, pancreas, heart, and insulinoma beta-cell lines ([@B17]). Wolframin is a transmembrane glycoprotein consisting of 890 amino acids with a molecular mass of 100.29 kD ([@B36]). It is composed of nine transmembrane segments and is embedded in the membrane with an N(cyt)/C(lum) topology ([@B17]). Its function has not yet been fully clarified. Some studies ([@B12]; [@B16]) have shown that *WFS1* appears to be important to the negative regulation of ER stress. [@B30] proposed that wolframin may play an important role in the regulation of intracellular Ca^2+^ homeostasis. In addition, [@B47] noted that an interaction with *WFS1* is essential for Na^+^/K^+^ ATPase beta-1 subunit maturation in the ER and that the loss of this interaction may contribute to the pathogenesis of WS1.

The Human Gene Mutation Database (HGMD) has so far recorded 393 variants in *WFS1*. Except for WS1, it is also thought to underlie some autosomal dominant conditions that are less severe. Given the clinical and genetic heterogeneity of WS1, combining genetic diagnosis with clinical features is an effective supplementary diagnostic method. In addition, genetic diagnosis is essential for prognosis evaluation, individualized treatment, genetic counseling and carrier screening. At present, limited data are available on which *WFS1* mutations are associated with WS1 in the Chinese population, and only a small number of case reports have been published. No prevalence has been reported in China. In this study, we used NGS to evaluate five Chinese patients affected by WS1, thus increasing the spectrum of *WFS1* mutations by adding four novel variants. We have also reviewed their clinical features.

Materials and Methods {#s2}
=====================

Subjects and Ethics Statement {#s2_1}
-----------------------------

We collected 279 patients with unexplained OA who presented at the Eye and ENT Hospital of Fudan University from 2016 to 2018. Patients with infection, ischemia, optic neuritis, myelitis, and tumors were excluded. The study was performed according to the Declaration of Helsinki and approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University. Written informed consent was obtained from all the subjects or their guardians to participate in this study and for the publication of these data.

Clinical Evaluations {#s2_2}
--------------------

All patients underwent detailed clinical evaluations, including medical history, family history, and basic and auxiliary examinations. The chief complaint, the course of the disease and accompanying symptoms were recorded in detail. In addition, every patient was asked whether his parents were consanguineous and whether other family members were affected. Basic and auxiliary examinations included best corrected visual acuity, tonometry, color vision (Ishihara color plate), slit-lamp examination, dilated fundus examination, frequency domain optical coherence tomography (Cirrus OCT 5000, Carl Zeiss Meditec, Inc., Dublin, CA, United States), Humphrey VisualField Analyzer (Carl Zeiss Meditec, Inc., Dublin, CA, United States), full-field electroretinography (ERG), and visual evoked potential (VEP) (LKC UTAS E3000 LKC Technologies, Inc., United States) tests. A preliminary assessment of systemic conditions was performed by measuring the fasting blood glucose concentration, pure-tone audiometry, and urine specific gravity. Orbital magnetic resonance imaging or computed tomography was used to exclude neoplasms.

Genetic Analyses {#s2_3}
----------------

We designed a high-throughput microarray in collaboration with BGI-Shenzhen (Shenzhen, Guangdong, China). It contained the exon sequences of 792 genes ([**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}) as well as 30 bp on either side of the exonic region, selected on the basis of OMIM database, the ophthalmic disease gene database, and related literature. Only genes known to be involved in human inherited eye diseases, including syndromes with ocular manifestation, were selected. Genes found only in animal models of eye diseases were not included. Genomic DNA was extracted from peripheral blood obtained from the probands and their family members using FlexiGene DNA Kits (Qiagen, Venlo, the Netherlands) according to standard procedures, sheared into 150--250 bp fragments, and captured with the Agilent SureSelect Target Enrichment Kit (Agilent Technologies, Inc., USA). Enriched libraries were sequenced on the Illumina HiSeq 2000 platform (Illumina, Inc., San Diego, CA, United States), and reads were aligned to the reference human genome (UCSC hg38) using the Burrows--Wheeler aligner version 0.7.10 (BWA-MEM). The following databases were used for the annotation: 1,000 Genomes Project, 1,000 Genomes in the East Asian population, Single Nucleotide Polymorphism Database, the Exome Aggregation Consortium, and Genome Aggregation Database. Then, we retained variants with a minor allele frequency (MAF) \< 0.1% to filter out possible non-deleterious variants based on MAF of each variant in these five databases. In addition, we performed the variant prioritizations based on MAF, potential deleterious effect and mutation reports in public databases such as HGMD, OMIM, and ClinVar. Furthermore, we analyzed the evolutionary conservation of the mutations online. Finally, Sanger sequencing and cosegregation analyses were performed within families. If no suspected pathogenic variant was found, Sanger sequencing was performed to check for the presence of the three primary mitochondrial DNA mutations (m.3460G \> A, m.11778G \> A, m.14484T \> C) ([@B46]). The cDNA NM_006005.3 and protein NP_005996.2 sequences were used for the mutation nomenclature. Variants were classified according to the American College of Medical Genetics.

Results {#s3}
=======

Of the 279 patients with unexplained OA, five from four unrelated families carried compound heterozygous mutations in *WFS1*, and all the variants cosegregated with the phenotypes observed in these families. The main clinical and genetic characteristics of the five patients are listed in [**Table 1**](#T1){ref-type="table"} and [**Table 2**](#T2){ref-type="table"}, and the pedigrees of the four families (A--D) are presented in [**Figure 1A**](#f1){ref-type="fig"}. Family history was clearly reported in three patients, whereas two patients were sporadic. Seven variants of *WFS1* were identified; these included four novel variants (p.W540G, p.K634\*, p.F770C, and p.Q584P) and three known variants (P.G674R, P.Tyr508Cysfs\*34, and P.G702D) ([@B20]; [@B2]; [@B14]). To date, 47 Chinese cases with WS1 have been published in pubMed (<Https://Www.Ncbi.Nlm.Nih.Gov/Pubmed/>), wanfang data (<Http://G.Wanfangdata.Com.Cn/Index.Html>), and China National Knowledge Infrastructure (<Http://Www.Cnki.Net/>) ([@B35]; [@B28]; [@B41]; [@B23]; [@B32]; [@B11]; [@B4]; [@B21]; [@B38]; [@B10]; [@B22]; [@B33]; [@B25]; [@B24]; [@B49]; [@B18]; [@B48]; [@B43]; [@B9]; [@B37]; [@B42]; [@B31]; [@B39]; [@B7]; [@B29]; [@B8]). However, only 10 patients were confirmed by genetic testing ([**Table 3**](#T3){ref-type="table"}), and only nine variants of *WFS1* have been reported in the Chinese population. Our study reports five Chinese patients and further enriches the spectrum of *WFS1* mutations. In addition, It is worth noting that c.2020G \> A(P.G674R) was recurrent in this study and was identified in two unrelated families. The allele frequency of this variant in East Asian populations is 0.000231965 according to the gnomAD database. Multiple orthologous sequence alignment (MSA) around codon 674 demonstrated this and neighboring residues are highly conserved amino acids in *WFS1* ([**Figure 2**](#f2){ref-type="fig"}). Furthermore, four prediction tools, including mutationtaster software, SIFT, LRT, and FATHMM, predicted that this variant is deleterious. Therefore, it suggested that p.G674R is likely to be a pathogenic variant with higher prevalence in the Chinese population.

![Pedigrees and identified variants in five Chinese patients with WS1. **(A)** Squares represent males, circles represent females, empty symbols represent normal controls, filled symbols represent affected patients, and arrows indicate the proband. **(B)** Sanger sequencing results for *WFS1* mutations in family A-1. Arrows indicate the positions of the variants.](fgene-10-01217-g001){#f1}

![Protein sequence alignment of human *WFS1* and its orthologs. Codon 674 and its subsequent sequences were highly conserved amino acids in *WFS1* across different species.](fgene-10-01217-g002){#f2}

###### 

Clinical characteristics and onset age of patients with WS1 in this study.

  Patient   Sex   Age   DM   OA   DI   HD   UD          ND   Other
  --------- ----- ----- ---- ---- ---- ---- ----------- ---- --------------
  A-1       M     26    11   7    --   26   --          --   --
  A-2       F     27    12   17   --   --   Nephritis   --   --
  B         F     12    --   9    --   --   --          --   --
  C         M     37    --   11   --   --   --          --   --
  D         M     28    8    8    --   --   28          28   Hypogonadism

M, male; F, female; DM, diabetes mellitus; OA, optic atrophy; DI, diabetes insipidus; HD, hearing defects; UD, urological or renal defects; ND, neurological defects; WS1, Wolfram syndrome type 1.

###### 

Mutations in *WFS1* found in 5 Chinese patients.

  Family   Exon   Nucleotide change   Amino acid change   Type of mutation   References
  -------- ------ ------------------- ------------------- ------------------ ------------
  A-1, 2   8      c.1618T \> G        p.W540G             Missense           This study
           8      c.2020G \> A        p.G674R             Missense           [@B20]
  B        8      c.1900A \> T        p.K634\*            Nonsense           This study
           8      c.2020G \> A        p.G674R             Missense           [@B20]
  C        8      c.1522_1523delTA    p.Tyr508Cysfs\*34   Frameshift         [@B2]
           8      c.2309T \> G        p.F770C             Missense           This study
  D        8      c.1751A \> C        p.Q584P             Missense           This study
           8      c.2105G \> A        p.G702D             Missense           [@B14]

All patients carried two compound heterozygous mutations in the WFS1 gene.

###### 

*WFS1* mutations previously identified in Chinese patients with WS1.

  Family   Exon   Nucleotide change      Amino acid change   Allele status   Type of mutation   References
  -------- ------ ---------------------- ------------------- --------------- ------------------ ------------
  E        8      c.1760G \> A           p.R587Q             Hom             Missense           [@B8]
  F        8      c.1250_1252delTCT      p.Phe417del         Hom             Deletion           [@B10]
  G        8      c.2411T \> C           p.L804P             Hom             Missense           [@B42]
  H        8      c.1300_1302delGTC      p.Val434del         Het             Deletion           [@B18]
           8      c.1997G \> A           p.W666\*            Het             Nonsense           [@B18]
  I        8      c.1300_1302delGTC      p.Val434del         Het             Deletion           [@B8]
           4      c.453_460delCAGAAGAG   p.Asp151Glufs\*93   Het             Frameshift         [@B8]
  J        8      c.1600T \> G           p.Y534D             Hom             Missense           [@B22]
  K        8      c\. 2196_2218del23bp   p.Cys733fs\*749     Hom             Frameshift         [@B31]
  L        4      c.433G \> A            p.C148Y             Hom             Missense           [@B29]

Het, heterozygous; Hom, homozygous; WS1, Wolfram syndrome type 1. The other two patients were identified as having three WFS1 mutations in exon 8, but detailed results were unavailable ([@B8]).

Family A {#s3_1}
--------

A 27-year-old female patient came for genetic testing. She was found to have DM when she was 12 years old and was diagnosed with bilateral OA 5 years later. In addition, her medical history revealed nephritis. She had an affected younger brother with similar symptoms. He presented with OA when he was 7 years old and was diagnosed with DM at the age of 11. Pure-tone audiometry revealed sensorineural hearing loss, while his urine-specific gravity was normal. Their vision was 20/400 OU. Genetic analysis identified a reported variant c.2020G \> A (p.G674R, inherited paternally) ([@B20]) and a novel variant c.1618T \> G (p.W540G, inherited maternally) of *WFS1* in both the proband and her brother ([**Figure 1B**](#f1){ref-type="fig"}). Parental examination and testing were normal.

Family B {#s3_2}
--------

A 12-year-old girl was found to have bilateral OA when she was 8 years old. She was the only affected family member. Past medical history showed a normal delivery, normal growth and development. Best corrected visual acuity was 20/30 with -4.50 sph OD and -0.25 sph OS, and color vision was abnormal. Frequency domain optical coherence tomography showed that the retinal nerve fiber layer (RNFL) and macular ganglion cell complex were thinning in four quadrants. The visual field revealed local decreased visual sensitivity in the right eye and a central scotoma in the left eye. Fundus examination showed that the temporal optic nerve was pale in the right eye and that all quadrants were pale in the left eye, while full-field ERG and VEP were normal. Orbital magnetic resonance imaging confirmed bilateral OA. In addition, pure-tone audiometry, urine specific gravity and fasting blood glucose concentration were normal. Genetic analysis showed a previously reported pathogenic variant associated with WS1 in her *WFS1* gene (c.2020G \> A, p.G674R) ([@B20]), which was inherited from her clinically normal mother. In addition, there was a novel variant c.1900A \> T (p.K634\*) identified in the girl, which was inherited from her clinically normal father.

Family C {#s3_3}
--------

A 37-year-old male patient came for evaluation of OA, with which he was diagnosed when he was 11 years old. Examination revealed visual acuity of 20/400 in each eye. Fundus examination showed pale optic discs in both eyes. Pattern VEP showed that the time to the P1 wave peak was delayed and its amplitude diminished. In addition, visual fields were constricted in both eyes. The peripapillary RNFL was thinning in the superior and inferior quadrants while macular ganglion cell complex was thinning in all four quadrants. Orbital computed tomography confirmed bilateral OA. He had no systemic findings. Pure-tone audiometry, urine specific gravity and fasting blood glucose concentration were normal. Genetic analysis found a reported variant c.1522_1523delTA (p.Tyr508Cysfs\*34, inherited paternally) ([@B2]) and a novel variant c.2309T \> G (p.F770C, inherited maternally) of *WFS1* in the proband. His mother was diagnosed with DM 10 years prior. Parental ophthalmic examination and testing were normal.

Family D {#s3_4}
--------

A 28-year-old male patient presented for genetic counseling. He presented with bilateral OA when he was 8 years old and was diagnosed with DM 20 years prior along with the clinical manifestations of polydipsia and polyuria. He presented with polyphagia and transient hand tremor for 3 months. In addition, he had enuresis, urgent and frequent urination, impotence, premature ejaculation and epididymitis. He had been constipated in recent months. Examination revealed visual acuity of 20/200 and 20/300 in the right and left eyes, respectively. The peripapillary RNFL showed thinning in the superior, temporal and inferior quadrants of the left eye, while thinning was found in all four quadrants of the right eye. VEP and ERG were abnormal, and he had visual field defects. Family history revealed that he had an affected sister who had poor vision since childhood and died of nephritis at the age of 25. Parental examination and testing were normal. Genetic analysis showed that he carried compound heterozygous mutations of *WFS1*: a reported variant c.2105G \> A (p.G702D, inherited maternally) ([@B14]) and a novel variant c.1751A \> C (p.Q584P, inherited paternally). His clinically normal son and daughter both carried a heterozygous variant c.1751A \> C (p.Q584P) of *WFS1*.

Discussion {#s4}
==========

In this study, by using genetic testing based on NGS we were able to diagnose five WS1 patients out of 279 patients with previously unexplained OA. The clinical diagnostic criteria for WS1 are juvenile-onset DM and OA. It is very difficult to diagnose WS1 at an early stage, and this is especially true for atypical WS1. NGS is a high-throughput approach for efficiently sequencing large gene pools at lower costs and can be used to identify rare disease genes. In families B and C, while the two probands presented with only OA, genetic analysis based on NGS made it possible to diagnose and confirm WS1 early. WS1 is a progressive neurodegenerative disease mainly affecting pancreatic beta cells and neuronal cells ([@B15]; [@B44]). Therefore, early diagnosis is crucial for patients and their families. This is beneficial to the systematic evaluation, monitoring and management of complications to improve the quality of life and delay the progression of the disease. Finally, it provides a genetic basis for carrier testing, and if desired, for preimplantation diagnostic testing.

Although the HGMD has recorded 263 *WFS1* mutations associated with WS1 thus far, 62.5% (5/8) of the mutations identified in our study were novel. Among the 263 identified mutations, there were 109 missense mutations, 50 nonsense mutations, 60 small deletion mutations, and 25 small insertion mutations. These mutations were mainly concentrated in exon 8. Khanim F et al.([@B20]) identified the mutations in *WFS1* in 90% of WS1 patients and found they were mainly compound heterozygous mutations, in accordance with our study. In family A, the proband and her brother had the same mutations in *WFS1*, but their phenotypes were not exactly the same. [@B5] evaluated six WS1 patients in five Italian families and noted that the same mutation could lead to different phenotypes, also consistent with our study. This finding suggested that the pathogenesis of WS1 was not only dependent on the mutation of *WFS1*, but also may be related to other genetic or environmental factors, such as modifier genes.

[@B6] analyzed genetic data in 412 WS1 patients reported since 1998, and found no major mutation hot spots; only the following six mutations were found in more than 5% of patients: c.2649delC (p.Phe884Serfs\*68, 7.42%), c.1230_1233del (p.Val412Serfs\*29, 6.82%), c.409_424dup (p.Val142Glyfs\*110, 6.53%), c.2119G \> A (p.V707I, 6.23%), c.1362_1377del (p.Tyr454\*, 5.64%), and c.1243_1245del (p.Val415del, 5.34%). In our study, c.2020G \> A (p.G674R) was the most prevalent alteration in our Chinese patients and was highly conserved in different species during evolution. This suggests that the mutation may impair the key functions of the protein. Several studies have reported that the variant c.2020G \> A (p.G674R) combined with c.2020G \> A (p.G674R) and c.1620delGTG (Trp540del) respectively resulted in the occurrence of WS1 ([@B20]; [@B1]). However, more samples are required to determine whether this is a common pathogenic variant in the Chinese population.

At present, only 47 Chinese WS1 patients have been reported since 1986. Furthermore, only 10 of these patients were confirmed by genetic testing. Given the specificity of ethnicity and the complexity of genotype-phenotype relationship, large cohort studies in the future are essential to elucidate the genotype--phenotype relationship of WS1 in the Chinese population. Our study further enriches the spectrum of *WFS1* mutations, which is currently based on limited data, making our findings of great significance, especially in the Chinese population.

Conclusion {#s5}
==========

NGS has become a powerful method for the detection of ophthalmic disorders with high clinical and genetic heterogeneity. Implementing comprehensive measures to slow the progression of diseases is essential not only in early diagnosis but also in risk evaluation, individualized treatment and carrier screening for probands and their families. Precise diagnosis based on clinical manifestation and genetic testing will become the gold standard for the diagnosis of hereditary eye diseases and syndromes in the future.
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